Loading...

TEVA - Teva Pharmaceutical Industries Limited

Analyst Downgrade Signal for 05-04-2022
Analyst Downgrade Signal: TEVA from Neutral to Underweight by Piper Sandler
Price Target: $11>>7


Loading Chart TEVA

Stock Signal Information


Signal

Analyst Downgrade Signal: TEVA from Neutral to Underweight by Piper Sandler
Price Target: $11>>7
Report Date: 05-04-2022
Symbol: TEVA - Teva Pharmaceutical Industries Limited
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Analyst Downgrade Signal: TEVA from Neutral to Underweight by Piper Sandler
Price Target: $11>>7

  TEVA Technical Analysis

Company Contact

Teva Pharmaceutical Industries Limited (TEVA)
5 Basel Street
Petah Tikva, 4951033
Phone: 972 3 914 8171
Website: http://www.tevapharm.com
CEO: Mr. Kre Schultz

TEVA, Teva Pharmaceutical Industries Limited

TEVA Teva Pharmaceutical Industries Limited Logo Image

NYSE, New York Stock Exchange


Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.